Related Experiment Video
Updated: Apr 25, 2026
07:54
Cholesterol Efflux Assay
Published on: March 6, 2012
29.4K
A review on lecithin:cholesterol acyltransferase deficiency
Ramesh Saeedi1, Min Li1, Jiri Frohlich1
1Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, Canada.
Clinical Biochemistry
|August 31, 2014
Summary
Lecithin cholesterol acyl transferase (LCAT) deficiency causes severe lipid disorders and organ damage. Recombinant LCAT shows promise for treating these rare genetic conditions.
Area of Science:
- Biochemistry
- Genetics
- Metabolic Diseases
Background:
- Lecithin cholesterol acyl transferase (LCAT) is crucial for high-density lipoprotein cholesterol (HDL-C) metabolism.
- Genetic LCAT disorders lead to abnormal lipoproteins and significant clinical manifestations.
- These include corneal opacities, erythrocyte changes, and renal failure.
Purpose of the Study:
- To investigate the role of LCAT in cholesterol metabolism.
- To understand the clinical and lipoprotein abnormalities in LCAT deficiency.
- To explore recombinant LCAT as a therapeutic option.
Main Methods:
- Enzyme activity assays.
- Lipoprotein analysis.
- Clinical case reviews.
- Biochemical studies.
Main Results:
- LCAT deficiency is linked to low HDL-C and the presence of lipoprotein X.
- Patients exhibit characteristic corneal, erythrocyte, and renal pathologies.
- Recombinant LCAT is under development for therapeutic intervention.
Conclusions:
- LCAT plays a vital role in HDL-C processing and overall lipid homeostasis.
- LCAT deficiency results in a distinct clinical syndrome requiring targeted treatment.
- Recombinant LCAT offers a potential therapeutic strategy for LCAT deficiency.
